← All trials
NCT06850480
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2024
- Primary completion
- Apr 15, 2025
- Completion date
- Apr 30, 2025
- First posted
- Feb 27, 2025
- Last posted
- Feb 27, 2025
- Enrollment
- 356
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Livzon Pharmaceutical Group Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.